

P- 2020/49694

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

DIRECCIÓN DE NUEVAS CREACIONES

E. S. D.

Re: Expediente No. **NC2020/0015168**Solicitud de patente a nombre de **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM**

Yo, CAROLINA DAZA MONTALVO identificada como aparece al pie de mi firma, domiciliada en la Carrera 11 No. 86-53, obrando como apoderada de la sociedad BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM., domiciliada en Texas, Estados Unidos de América, solicitante de la patente de la referencia, en respuesta al oficio No. **1041** notificado electrónicamente el 24 de enero de 2024, relacionado con los requerimientos de fondo de la solicitud, y para el cual oportunamente solicité prórroga el 17 de abril de 2024, atentamente me permito presentar la siguiente información:

1. Título

El examinador afirma que el título de la invención "CÉLULAS ASESINAS NATURALES DISEÑADAS PARA EXPRESAR RECEPTORES DE ANTÍGENO QUIMÉRICO CON BLOQUEO DE PUNTOS DE CONTROL INMUNITARIO" no se relaciona con el objeto de la solicitud contenida en las reivindicaciones.

Para superar la objeción, el solicitante modifica el título como se muestra a continuación: "CÉLULAS ASESINAS NATURALES QUE EXPRESAN UN RECEPTOR DE ANTÍGENO QUIMÉRICO, IL-15 Y QUE NO EXPRESAN EL GEN CISH".

2. Modificación al capítulo reivindicatorio:

Con fundamento en la facultad que confiere el artículo 34 de la Decisión 486 al solicitante para modificar la solicitud de patente en cualquier momento del trámite, presento junto a este memorial un nuevo capítulo reivindicatorio que consta de treinta y cinco (35) reivindicaciones,

el cual reemplaza completamente el documento presentado el 2 de diciembre de 2020. Específicamente, se realizaron las siguientes modificaciones:

- 1.1 Se modificó la reivindicación 1 con el fin de:
 - 1.1.1 Restringir el diseño de la célula para expresar únicamente un receptor de antígeno quimérico (CAR).
 - 1.1.2 Eliminar el término "esencialmente".
- 1.2 Se eliminaron las reivindicaciones 3 y 38 a 54. Además, se ajustó la numeración del documento.
- 1.3 Se modificó la antigua reivindicación 4 (nueva reivindicación 3), con el fin de eliminar la referencia a que la célula NK modificada expresa un receptor de células T(TCR).
- 1.4 Se unificaron las antiguas reivindicaciones 10 y 11, en la nueva reivindicación 9.
- 1.5 Se modificó el preámbulo de las antiguas reivindicaciones 10, 12 y 13 (nuevas reivindicaciones 9, 10 y 11), de modo que ahora se refieren a la población de células NK y no a un método.
- 1.6 Se modificó la antigua reivindicación 14 (nueva reivindicación 12), con el fin de:
 - 1.6.1 Aclarar que el método hace referencia a un método *in vitro*. Esta modificación se sustenta, por ejemplo, en los párrafos [0006], [00073] y [00234] de la descripción.
 - 1.6.2 Incluir las características que definen la población de células NK que se producen en el método, de conformidad con la reivindicación independiente 1.
 - 1.6.3 Señalar que las células NK se obtienen de sangre de cordón umbilical. Esta modificación se sustenta, por ejemplo, en el párrafo [0008] de la descripción.

Estas modificaciones no amplían de ninguna manera la materia objeto de la presente solicitud, ya que se encuentran sustentadas tanto en la descripción, y se realizan con el fin de definir la materia reclamada de forma clara y superar las objeciones planteadas por el examinador en su concepto técnico.

3. Pago de tasas

Considerando que el presente memorial se presenta junto con modificaciones a las reivindicaciones, se adjunta recibo por concepto de pago de tasa de modificación a la solicitud, según lo establecido en la **Resolución 59669 de 2020**.

Ahora, en relación con el número de reivindicaciones, atentamente me permito resaltar que junto a la presente respuesta no se realiza el pago de la tasa por concepto de reivindicaciones adicionales, dado que el nuevo capítulo reivindicatorio cuenta con un menor número de cláusulas que el presentado y estudiado anteriormente por su despacho.

Por otra parte, es deseo del solicitante requerir que, si el examinador considera que aún existen motivos que impidan la concesión de la solicitud, proceda a emitir un nuevo examen de patentabilidad, para lo cual se anexa el respectivo pago de nuevo examen.

4. Excepción de patentabilidad

El examinador objeta el contenido de la reivindicación 39 debido a que reclama una composición *"para uso en el tratamiento de una enfermedad o trastorno en un sujeto"*, lo cual es considerado como materia no patentable de conformidad con lo establecido en el artículo 20 inciso d) de la Decisión 486 de 2000 al hacer referencia a métodos de tratamiento o cantidades de dicha composición para ser administrada a un sujeto para tratar enfermedades o trastornos.

De manera similar, el examinador objeta las reivindicaciones 32 a 37, debido a que harían referencia a un método para producir células NK en donde dichas células son autólogas. Según el examinador, dicho termino hacer referencia a trasplantes lo que equivale a un proceso terapéutico exceptuado de patentabilidad.

Por último, el examinador objeta las reivindicaciones 41 a 54 debido a que reclaman un método para tratar un trastorno relacionado con el sistema inmune en un sujeto, que comprende administrar una cantidad eficaz de células NK al sujeto.

En ese sentido, el solicitante manifiesta respetuosamente su desacuerdo. Sin embargo, con el fin de contribuir a dar continuidad al proceso, el solicitante ha decidido eliminar las reivindicaciones 39 y 41 a 54.

En relación con las reivindicaciones 32 a 37, el solicitante no está de acuerdo con que se refieran a materia no patentable, dado que el término "autólogo" se relaciona como tal con el origen de la célula y no necesariamente implica un procedimiento de trasplante terapéutico. Adicionalmente, es importante resaltar que dichas reivindicaciones 32 a 37 (nuevas reivindicaciones 30 a 35), dependen de la nueva reivindicación 12, la cual ha sido modificada para caracterizar adecuadamente la población de células NK a la que se refiere de conformidad con la reivindicación independiente 1 y se ha aclarado que el método para producir dichas células corresponde a un método *in vitro* de conformidad con los párrafos [0006], [00073] y [00234] de la descripción.

Por último, me permito resaltar las disposiciones que sobre el asunto menciona el Manual Andino de Patentes con respecto a qué se debe considerar como un método terapéutico:

*Si el método implica la administración de un producto (compuesto o composición farmacéutica, por ejemplo) a un sujeto humano o animal con el propósito de prevenir, curar o aliviar una enfermedad, o de corregir o reparar las secuelas de esta; entonces la materia reivindicada es un método terapéutico. **En la medida que el método no implique la administración de un producto a un sujeto humano o animal, lo solicitado no debe ser considerado un método terapéutico...** " (Pág. 85, Manual Andino de Patentes, 2022)*

Por lo tanto, aunque en las reivindicaciones se utilizan términos relacionados con el origen de la células en cuestión, no se relacionan con un método que implique la administración de las células a un ser humano o un animal, por lo que las reivindicaciones no deben ser consideradas como métodos de tratamiento.

En ese sentido, se entendería el método *in vitro* y el carácter autólogo de las células hacen referencia al origen de las células a modificar y diseñar en el método *in vitro*, evitando cualquier referencia a un posible tratamiento. En ese sentido, se solicita la reconsideración de la objeción.

5. Reivindicaciones relativas a un uso

El examinador objeta la reivindicación 40, debido a que , dado que se refieren al uso de la composición que comprende una cantidad eficaz de células NK, se considera materia no

patentable de conformidad con el artículo 14 de la Decisión 486 de 2000, la cual establece que solo son patentables invenciones de producto o procedimiento.

El solicitante respetuosamente manifiesta su desacuerdo con la opinión del examinador. Sin embargo, con el fin de contribuir a dar continuidad al examen de la solicitud se ha eliminado dicha reivindicación. En ese sentido es posible dar por superada la presente objeción.

6. Claridad y concisión de las reivindicaciones

El solicitante manifiesta que mediante la presentación del nuevo capítulo reivindicatorio quedan subsanadas la totalidad de las objeciones presentadas por el examinador en su concepto técnico, de modo tal que las nuevas reivindicaciones reclaman de manera clara y concisa la invención descrita. Con respecto a las objeciones específicas del examinador, me permito manifestar lo siguiente:

- 6.1** El examinador considera que la reivindicación 1 no es clara ni se sustenta en la descripción, porque reclama una célula asesina natural NK, sin incluir características técnicas esenciales que permitan delimitar el alcance de la invención. En ese sentido el examinador sugiere incluir las secuencias de nucleótidos o aminoácidos que definen los transgenes o proteínas introducidas o modificadas, es decir, incluyendo la secuencia del vector viral que codifica los transgenes o del inserto genómico resultante de su inserción. Adicionalmente, sugiere eliminar el término “esencialmente” ya que se considera impreciso para definir la expresión de CISH.

En este sentido el solicitante respetuosamente manifiesta su desacuerdo con la opinión del examinador, debido a que es una restricción que no resulta necesaria para definir el alcance de las células NK. Por el contrario, el solicitante sostiene que una persona versada en la materia estaría en la capacidad de identificar la estructura del CAR, hIL-15 y el gen CISH, de conformidad con lo establecido en la descripción y el conocimiento usual del campo técnico.

Adicionalmente en las reivindicaciones 12 a 35 se señala el método a partir del cual se producen dichas células. Por ende, el tipo de célula de la reivindicación 1 y el método para su producción, permiten establecer de manera inequívoca el alcance de la invención que sería comprendido por una persona versada en la materia. En ese sentido, se solicita reconsiderar dicha objeción.

- 6.2** Por otra parte el examinador objeta las reivindicaciones 1, 3, 4 y 8 debido a que carecen de sustento en la descripción al reclamar una célula NK diseñada para expresar un TCR, pero, todas las células diseñadas exploradas en la descripción expresan únicamente un receptor de antígeno quimérico (CAR) y no un TCR.

El solicitante manifiesta respetuosamente su desacuerdo, sin embargo, con el fin de contribuir a la continuidad del proceso, se ha decidido eliminar la referencia a los receptores de células T de dichas reivindicaciones y restringir los diseños de las células NK, únicamente a células NK que expresan receptores de antígeno quimérico (CAR). En ese sentido, es posible dar por superada la objeción.

- 6.3** Adicionalmente el examinador objeta la reivindicación 8 por carecer de sustento en la descripción dado que reclama una célula NK diseñada para expresar un CAR o un TCR que tiene especificidad antigénica por hasta 44 antígenos. Sin embargo, la solicitud únicamente evidencia células NK diseñadas para expresar un CAR anti-CD19.

Al respecto, el solicitante desea aclarar que, si bien la evidencia suministrada en la descripción hace referencia a células NK diseñadas para que expresen un CAR anti-CD19, esto no implica que esta sea la única manera de poner en práctica la invención y mucho menos que la persona normalmente versada en la materia no pueda comprender que el efecto demostrado pueda ser extrapolado para otros antígenos. De hecho, una persona versada en la materia estaría en la capacidad de tener en cuenta las características de las células y los métodos divulgados en la descripción de la solicitud para aplicar en la expresión de receptores CAR en relación a otros antígenos, tal como se sustenta entre los párrafos [000108] y [000111] de la descripción. En ese sentido, amablemente se solicita dar por superada la presente objeción.

- 6.4** Por otra parte, el examinador considera que las reivindicaciones 10 y 11 tampoco se encuentran sustentadas en la descripción porque hacen referencia a que las células NK expresan una segunda citoquina, sin embargo, en la descripción únicamente hay un sustento por una única citoquina (IL-15).

El solicitante respetuosamente discrepa de la opinión del examinador y señala que aplicar la invención a células que expresan IL-21 o IL-12, es una razonable generalización de la materia ejemplificada, en donde se emplea una citocina IL-15. En este sentido, el solicitante sostiene que una persona normalmente versada en la materia sabría comprender y adaptar sin ningún inconveniente el desarrollo de la invención a células que expresen otras citoquinas, como las

mencionadas en las reivindicaciones objetadas. En ese sentido, amablemente se solicita reconsiderar y dar por superada la presente objeción.

6.5 Las reivindicaciones 10 a 12, también son objetadas por el examinador debido a que presentan errores de dependencia al referirse a “método de la reivindicación 1”, sin embargo, dicha reivindicación reclama la célula NK modificada. Adicionalmente, el examinador opina que carecen de claridad al incluir las expresiones “ha activado un objetivo mamífero de señalización de rapamicina (mTOR)” o “tiene una señalización JAK/STAT aumentada”, lo cual hace referencia a resultados a alcanzar y no permiten definir el alcance de la materia a reclamar.

En este sentido, el solicitante amablemente ha decidido atender a la sugerencia del examinador y ha modificado el preámbulo de las antiguas reivindicaciones 10 a 12 (nuevas reivindicaciones 9 a 11), con el fin de que reclamen células NK de conformidad con las reivindicaciones de las que depende.

En relación con los resultados a alcanzar es importante mencionar que, al encontrarse en reivindicaciones dependientes, dichas características no buscan delimitar el alcance de la invención sino describir las características funcionales de la misma, con base en el efecto técnico alcanzado y demostrado en la descripción. En ese sentido, son características complementarias que no afectan la claridad de la materia a reclamar, por lo que el solicitante considera deberían ser permisibles para estas reivindicaciones dependientes.

En vista de lo anterior, amablemente se solicita reconsiderar y dar por superada la presente objeción.

6.6 El examinador también objeta las reivindicaciones 14 a 17, debido a que considera que no se encuentran sustentadas en la descripción debido a que no incluyen todas las características técnicas esenciales que permiten delimitar el alcance del método, es decir incluyendo condiciones y etapas específicas. Por lo tanto, el examinador sugiere definir cada una de las características a partir de una razonable generalización de la materia encontrada en la descripción.

En este sentido, el solicitante respetuosamente discrepa de la opinión del examinador dado que, requerir que se establezcan características técnicas específicas sugeridas por el examinador resultaría en una restricción innecesaria de la materia reclamada. De este modo, el solicitante manifiesta que una persona versada en la materia estaría en la capacidad de incluir las condiciones que considere con el fin de cumplir con los pasos establecidos en la antigua reivindicación 14 (nueva reivindicación 12) de acuerdo con el conocimiento general del campo técnico y teniendo en cuenta las características de las reivindicaciones dependientes 15 a 17 (nuevas reivindicaciones 13 a 15). Por ende, amablemente se solicita reconsiderar y dar por superada la presente objeción.

6.7 Por último, el examinador objeta la reivindicación 38, debido a que caracteriza la composición con célula NK por el método de producción de las reivindicaciones 14 a 37. Sin embargo, dichas células podrían caracterizarse a partir de las secuencias de sus transgenes y/o insertos génicos.

Sin estar de acuerdo con la opinión del examinador, pero con el fin de contribuir al proceso, el solicitante ha decidido eliminar dicha reivindicación 38 del capítulo reivindicatorio. En ese sentido es posible dar por superada la presente objeción.

En vista de lo anterior, las objeciones relacionadas con la claridad, la concisión y el soporte en la descripción del capítulo reivindicatorio, han quedado completamente superadas.

7. Descripción

El examinador indica que la descripción no divulga la materia reclamada de manera suficiente para que una persona normalmente versada en la materia pueda ejecutarla o reproducirla, por lo que no cumpliría con las disposiciones del Art. 28 de la Decisión Andina 486.

En este sentido, el examinador señala que el capítulo reivindicatorio carece de sustento en la descripción debido a que no caracteriza de forma adecuada las células NK modificadas que expresan receptores CAR y TCR, o los métodos para su obtención. En ese sentido, sugiere restringir las características de las células de acuerdo con la evidencia técnica concreta y explícita demostrada en la descripción, que se refiere a células transfetadas con el vector viral iC9.CAR19.CD28-zeta-2A-IL-15 que expresan un CAR anti-CD19 y la IL-15 y que han sido editadas empleando el sistema CRISPR/Cas9 con los ARN guía SEQ ID NO: 1 y 2 y la nucleasa Cas9 para el silenciamiento del gen CISH y, para los métodos de producción comprenden: el co-

cultivo y expansión con células APC en una proporción 1:2 de células NK por células APC, la introducción del vector viral iC9.CAR19.CD28-zeta-2A-IL-15 y el silenciamiento mediado por CRISPR/Cas9 del gen CISH con los ARN guía SEQ ID NO: 1 y 2 y la nucleasa Cas9, tal como establecen las páginas 104 a 127 de la descripción.

Al respecto, el solicitante afirma que una persona versada en la materia de los métodos de producción de terapia celular consideraría innecesarios los detalles requeridos por el examinador, toda vez que, al tener experiencia en la técnica, consideraría que esas condiciones y pasos son rutinarios y no afectan la claridad ni el sustento de la materia reclamada. Además, como ya bien se explicó, la manera en que se divulga la materia en las reivindicaciones es suficiente para comprender el alcance de la invención y relacionarlo directamente con la evidencia suministrada en la descripción. En ese sentido, amablemente se solicita reconsiderar y dar por superada la presente objeción.

De esta manera, la materia divulgada en la descripción ahora se relaciona de una manera más cercana con la materia definida en el capítulo reivindicatorio. Por lo tanto, la descripción proporciona toda la información necesaria para llevar a cabo la invención y cumple con los requisitos legales establecidos en la Decisión Andina 486.

8. Nivel inventivo

El examinador ha indicado que las reivindicaciones 1 a 31 y 38 carecerían de nivel inventivo en vista de las enseñanzas del documento D1 (Liu, E., Leukemia, "Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity" y D2 (WO2017123956).

Con respecto a lo anterior, me permito resaltar las disposiciones del artículo 18 de la Decisión 486 de la Comisión de la Comunidad Andina, que establecen que *"se considerará que la invención tiene nivel inventivo, si para una persona del oficio normalmente versada en la materia técnica correspondiente, esa invención no hubiese resultado obvia ni se hubiese derivado de manera evidente del estado de la técnica"*.

Lo anterior significa que el análisis de nivel inventivo **NO** es una comparación de los objetos de las anterioridades y la solicitud en estudio. Por el contrario, el análisis de nivel inventivo **debe demostrar** la obviedad de la invención y establecer cómo ésta no contiene un salto cualitativo, que demuestre su altura inventiva, teniendo en cuenta que se hace **necesario demostrar** que

la invención analizada carece de nivel inventivo y hubiese sido obvia para una persona versada en la materia.

Ahora bien, dichas condiciones no se cumplen para el caso en cuestión, pues, tal como se mostrará a continuación, las características técnicas mencionadas en las reivindicaciones independientes no pueden derivarse de manera obvia o evidente a partir de las enseñanzas del estado de la técnica representadas en los documentos D1 y D2, y, por lo tanto, la materia reclamada es inventiva a la luz del arte previo.

El análisis del examinador

El examinador señala que el documento D1 es considerado como el estado de la técnica más cercano a la invención definida en la reivindicación 1, ya que divulga células NK transducidas con un vector retroviral iC9/CAR.19/IL15 que incorpora el gen para CAR.19 y expresa IL-15 y un gen suicida inducible de caspasa 9.

Ahora, es importante resaltar que el examinador reconoció que la principal diferencia entre las células NK divulgadas en la reivindicación 1 y las células divulgadas en el documento D1, es que que las células de la solicitud no tienen esencialmente expresión de CISH.

Sin embargo, el examinador considera que tal diferencia no está asociada a un efecto técnico, ya que la solicitud no ha incluido todas las características técnicas esenciales que delimiten adecuadamente la población de células NK modificadas, y que permitan relacionar las células NK con el efecto técnico que reclama la invención.

Asimismo, el examinador menciona que el documento D1 ya menciona una célula que comprende: al menos un receptor diseñado que es un receptor de antígeno quimérico (CAR) o un receptor de (TCR), al menos un elemento adenoviral extracromosomal y al menos una delección de un gen endógeno. Además, el documento D2 ya sugiere que el gen endógeno es un punto de control inmune a considerar en la modificación de la célula.

Por lo tanto, el examinador considera que la persona normalmente versada en la materia estaría motivada a considerar D2 en relación con la célula propuesta en D1, haciendo que la materia reclamada fuese obvia.

La materia reclamada es inventiva a la luz del arte previo citado

Visto lo anterior, el solicitante desea manifestar respetuosamente su desacuerdo con la opinión del examinador.

El efecto técnico de la diferencia reconocida por el examinador (esto es, que las células no expresen CISH) se demuestra en la figura 3 de la presente solicitud. En particular, las figuras 3A a 3D muestran que i) el knockout de CISH y ii) la transducción con una transducción de CAR e IL-15 mejoran sinérgicamente la función y la citotoxicidad de las células NK (véase el párrafo [00030] de la presente solicitud). Las células NK diseñadas para expresar IL-15 y carecen de CISH (como se define en la reivindicación 1) son, por lo tanto, ventajosas sobre las células NK de D2 que expresan tanto IL-15 como CISH. La ventaja, es decir, la mejora sinérgica de la función de las células NK y la citotoxicidad, no se podía haber predicho.

Adicionalmente el carácter inventivo de la materia reclamada se demuestra en el segundo anexo de este memorial, en donde se da evidencia que, para las células NK, la presencia de IL-15 en la construcción de CAR en las células NK es necesaria, al menos para la mejora de la función de las células NK mediada por CISH KO. Tal requisito no podría haber sido esperado por una persona versada en la materia al estudiar el contenido de los documentos D1 y D2.

Por lo tanto, la única razón para considerar que la invención actualmente reivindicada, es que el examinador conoce sus características de antemano.

Teniendo en cuenta lo anteriormente expuesto, queda claro que las características técnicas de la materia definida en el capítulo reivindicatorio presentado junto al presente memorial no se derivan de manera obvia o evidente de las enseñanzas de D1 y D2. Por lo tanto, el objeto reclamado cumple con el requisito de Nivel inventivo establecido en el Art. 18 de la Decisión 486.

9. Conclusión

Con las modificaciones introducidas y los argumentos presentados puede concluirse que:

- i) El nuevo título de la solicitud es claro y se relaciona con el objeto reclamado, cumpliendo así con el literal d) del artículo 27 de la Decisión 486 de 2000;

- ii) El nuevo pliego reivindicatorio se ajusta a las disposiciones del Artículo 34 de la Decisión 486/00;
- iii) La invención de la presente solicitud es clara y cuenta con el debido sustento en el capítulo descriptivo, a la vez que se encuentra divulgada de manera suficientemente completa, cumpliendo así con los requerimientos de los Artículos 30 y 28 de la Decisión 486;
- iv) La presente invención se relaciona con materia susceptible de patentabilidad, cumpliendo así con los requerimientos del Artículo 14 de la Decisión 486;
- v) La invención de la presente solicitud no resulta obvia ni se derivada de manera evidente del estado de la técnica, cumpliendo así con los requerimientos del Artículo 18 de la Decisión 486

Por tanto, atentamente me permito solicitar a ese Despacho otorgar el privilegio de patente solicitado a la solicitud en estudio, toda vez que cumple a cabalidad con los requerimientos de la Decisión 486 de 2000.

Asimismo, respetuosamente solicito a ese Despacho pronunciarse en relación con todos los argumentos presentados en este memorial dando estricta aplicación al principio del debido proceso consagrado en el artículo 29 de la Constitución Nacional.

10. Anexos

- Nuevo capítulo reivindicatorio conformado por treinta y cinco (35) reivindicaciones.
- Daher, M., Basar, R., Gokdemir, E., et al. (2021). Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. *Blood*, 137(5), 624–636. <https://doi.org/10.1182/blood.2020007748>
- Recibo de pago por concepto de modificaciones a las reivindicaciones y nuevo examen de patentabilidad.

Señora Directora,



CAROLINA DAZA MONTALVO

C.C. 66.783.790 de Palmira Valle

TP-141563 CSJ

notificaciones@clarkemodet.com.co

REIVINDICACIONES

1.
- Una célula asesina natural (NK) aislada diseñada para expresar (1) un receptor de antígeno quimérico (CAR) y (2) IL-15 humana (hIL-15) y para no tener expresión de CISH.
2.
- La célula NK de la reivindicación 1, en la que la célula NK está diseñada para expresar un CAR.
3.
- La célula NK de la reivindicación 1, en la que la célula NK está diseñada para expresar un CAR.
4.
- La célula NK de la reivindicación 1, en la que la célula NK se deriva de sangre de cordón, sangre periférica, médula ósea, células CD34⁺ o iPSC.
5.
- La célula NK de la reivindicación 1, en la que la célula NK se deriva de la sangre del cordón.
6.
- La célula NK de la reivindicación 5, en la que la sangre del cordón se ha congelado previamente.
7.
- La célula NK de la reivindicación 1, en la que el CAR tiene especificidad antigénica para ligandos CD19, CD319/CS1, ROR1, CD20, CD5, CD7, CD22, CD70, CD30, BCMA, CD25, NKG2D, MICA/MICB, antígeno carcinoembrionario, alfafetoproteína, CA-125, MUC-1, antígeno tumoral epitelial, antígeno asociado a melanoma, p53 mutado, ras mutado, HER2/Neu, ERBB2, proteína de unión a folato, glicoproteína gp120 de la

envoltura del HIV-1, glicoproteína gp41 de la envoltura del HIV-1, GD2, CD123, CD33, CD30, CD56, c-Met, mesotelina, GD3, HERV-K, IL-11Ralfa, cadena kappa, cadena lambda, CSPG4, ERBB2, WT-1, EGFRvIII, TRAIL/DR4 y/o VEGFR2.

- 5
8. La célula NK de la reivindicación 1, en la que el CAR tiene especificidad antigénica para CD19.
9. La célula NK de la reivindicación 1, en el que la célula NK expresa además una segunda citoquina, en donde la citoquina es IL-21 o IL-12.
- 10
10. La célula NK de cualquiera de las reivindicaciones 1-9, en el que la célula NK ha activado un objetivo mamífero de señalización de rapamicina (mTOR).
- 15
11. La célula NK de la reivindicación 10, en el que la célula NK tiene una señalización JAK/STAT aumentada.
- 20
12. Un método *in vitro* para producir células NK de cualquiera de las reivindicaciones 1-11, en donde la célula NK es célula asesina natural (NK) aislada diseñada para expresar (1) un receptor de antígeno quimérico (CAR) y (2) IL-15 humana (hIL-15) y no tener expresión de CISH, en el que el método comprende:
- 25
- (a) obtener una población inicial de células NK a partir de sangre de cordón umbilical;
- (b) cultivar la población inicial de células NK en presencia de células presentadoras artificiales (APC);

- (c) introducir un vector de expresión CAR y/o TCR en las células NK;
- (d) expandir las células NK en presencia de APC, obteniendo así células NK expandidas; y
- (e) interrumpir la expresión de CISH en las células NK expandidas.

5

13. El método de la reivindicación 12, en el que interrumpir la expresión comprende utilizar silenciamiento génico mediado por CRISPR.

10

14. El método de la reivindicación 13, en el que el silenciamiento génico mediado por CRISPR comprende poner en contacto las células CAR NK con sgRNA y Cas9.

15. El método de la reivindicación 12, en el que el sgRNA se dirige al exón 4 de CISH.

15

16. El método de la reivindicación 15, en el que el sgRNA comprende las SEQ ID NO: 1-2.

20

17. El método de la reivindicación 12, en el que la población de partida de células NK se obtiene aislando células mononucleares usando un gradiente de densidad ficoll-paque.


18. El método de la reivindicación 12, en el que las APC son APC irradiadas con rayos gamma.

25

19. El método de la reivindicación 12, en el que las APC son APC universales (uAPC).

20. El método de la reivindicación 12, en el que las APC están diseñadas para expresar 41BB e IL-21.
21. El método de la reivindicación 19, en el que las uAPC están diseñadas para expresar (1) CD48 y/o CS1 (CD319), (2) interleuquina-21 unida a la membrana (mbIL-21) y (3) ligando 41BB (41BBL)).
22. El método de la reivindicación 12, en el que las células NK y las APC están presentes en una proporción de 1:2.
23. El método de la reivindicación 12, en el que las células NK de las etapas (b) y (d) se expanden adicionalmente en presencia de IL-2.
24. El método de la reivindicación 23, en el que IL-2 está presente en una concentración de 100-300 U/ml.
25. El método de la reivindicación 23, en el que IL-2 está presente en una concentración de 200 U/mL.
26. El método de la reivindicación 12, en el que la introducción comprende la transducción.
27. El método de la reivindicación 12, en el que el constructo de expresión de CAR y/o TCR es un vector lentiviral o retroviral.
28. El método de la reivindicación 12, en el que las células NK son compatibles con GMP.

29. El método de la reivindicación 12, en el que las células NK son alogénicas.
30. El método de la reivindicación 12, en el que las células NK son autólogas.
31. El método de la reivindicación 12, donde el CAR y/o TCR tienen
5 especificidad antigénica para ligandos CD19, CD319/CS1, ROR1, CD20, CD5, CD7, CD22, CD70, CD30, BCMA, CD25, NKG2D, MICA/MICB, antígeno carcinoembrionario, alfafetoproteína, CA-125, MUC-1, antígeno tumoral epitelial, antígeno asociado a melanoma, p53 mutado, ras mutado, HER2/Neu, ERBB2, proteína de unión a folato, glicoproteína gp120 de la
10 envoltura del HIV-1, glicoproteína gp41 de la envoltura del HIV-1, GD2, CD123, CD23, CD30, CD56, c-Met, mesotelina, GD3, HERV-K, IL-11Ralfa, cadena kappa, cadena lambda, CSPG4, ERBB2, WT-1, EGFRvIII, TRAIL/DR4 y/o VEGFR2.
- 15 32. El método de la reivindicación 12, en el que el CAR tiene especificidad antigénica para CD19.
33. El método de la reivindicación 12, en el que el constructo de expresión de CAR y/o TCR expresa además una citoquina.
20
34. El método de la reivindicación 33, en el que la citoquina es IL-15, IL-21 o IL-12.
35. El método de la reivindicación 12, que comprende además criopreservar la
25 población de células NK expandidas.



IMMUNOBIOLOGY AND IMMUNOTHERAPY

Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells

May Daher,^{1,*} Rafet Basar,^{1,*} Elif Gokdemir,¹ Natalia Baran,² Nadima Uprety,¹ Ana Karen Nunez Cortes,¹ Mayela Mendt,¹ Lucila Nassif Kerbauy,^{1,3,4} Pinaki P. Banerjee,¹ Mayra Shanley,¹ Nobuhiko Imahashi,¹ Li Li,¹ Francesca Lorraine Wei Inng Lim,¹ Mohsen Fathi,⁵ Ali Rezvan,⁵ Vakul Mohanty,⁶ Yifei Shen,⁶ Hila Shaim,¹ Junjun Lu,¹ Gonca Ozcan,¹ Emily Ensley,¹ Mecit Kaplan,¹ Vandana Nandivada,¹ Mustafa Bdiwi,¹ Sunil Acharya,¹ Yuanxin Xi,⁶ Xinhai Wan,¹ Duncan Mak,² Enli Liu,¹ Xin Ru Jiang,¹ Sonny Ang,¹ Luis Muniz-Feliciano,¹ Ye Li,¹ Jing Wang,⁶ Shahram Kordasti,⁷ Nedyalko Petrov,⁷ Navin Varadarajan,⁵ David Marin,¹ Lorenzo Brunetti,⁸ Richard J. Skinner,⁹ Shangrong Lyu,⁹ Leiser Silva,⁹ Rolf Turk,¹⁰ Mollie S. Schubert,¹⁰ Garrett R. Rettig,¹⁰ Matthew S. McNeill,¹⁰ Gavin Kurgan,¹⁰ Mark A. Behlke,¹⁰ Heng Li,¹¹ Natalie W. Fowlkes,¹² Ken Chen,⁶ Marina Konopleva,² Richard E. Champlin,¹ Elizabeth J. Shpall,¹ and Katayoun Rezvani¹

¹Department of Stem Cell Transplantation and Cellular Therapy and ²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; ³Department of Stem Cell Transplantation and Cellular Therapy, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ⁴Human Genome and Stem Cell Research Center, Department of Genetics and Evolutionary Biology, Biosciences Institute, University of Sao Paulo, Sao Paulo, Brazil; ⁵Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX; ⁶Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX; ⁷System Cancer Immunology, Comprehensive Cancer Centre, King's College London, London, United Kingdom; ⁸Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; ⁹C.T. Bauer College of Business, University of Houston, Houston, TX; ¹⁰Integrated DNA Technologies, Coralville, IA; ¹¹Dana-Farber/Harvard Cancer Center, Boston, MA; and ¹²Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

KEY POINTS

- CRISPR-Cas9 *CISH* deletion enhances the metabolic fitness and antitumor activity of armored IL-15-secreting CB-derived CAR-NK cells.

Immune checkpoint therapy has resulted in remarkable improvements in the outcome for certain cancers. To broaden the clinical impact of checkpoint targeting, we devised a strategy that couples targeting of the cytokine-inducible Src homology 2-containing (CIS) protein, a key negative regulator of interleukin 15 (IL-15) signaling, with fourth-generation “armored” chimeric antigen receptor (CAR) engineering of cord blood–derived natural killer (NK) cells. This combined strategy boosted NK cell effector function through enhancing the Akt/mTORC1 axis and c-MYC signaling, resulting in increased aerobic glycolysis. When tested in a lymphoma mouse model, this combined approach improved NK cell antitumor activity more than either alteration alone, eradicating lymphoma xenografts

without signs of any measurable toxicity. We conclude that targeting a cytokine checkpoint further enhances the antitumor activity of IL-15–secreting armored CAR-NK cells by promoting their metabolic fitness and antitumor activity. This combined approach represents a promising milestone in the development of the next generation of NK cells for cancer immunotherapy. (*Blood*. 2021;137(5):624-636)

Introduction

Natural killer (NK) cells mediate potent cytotoxicity against tumor cells¹ and are attractive candidates for the next-generation cancer immunotherapies.² Moreover, their ready availability from various sources, such as umbilical cord blood (CB), boosts their potential as a third-party product for widespread clinical scalability.^{3,4} A recent advance in the development of NK-cell–based immunotherapy is the demonstration that chimeric antigen receptor (CAR) engineering can enhance their effector function.⁵⁻⁷ We have shown that CB-NK cells transduced with a fourth-generation vector encoding anti-CD19 CAR and interleukin-15 (IL-15) induce greater *in vivo* expansion and longer-term persistence than nontransduced (NT) NK cells.⁶ While our preclinical study using an aggressive model of NK-resistant Raji lymphoma confirmed that this approach can prolong survival of mice,⁶ it was not curative, leading us to question

whether the antitumor activity of IL-15–secreting CAR-NK cells could be further enhanced by inhibiting key cytokine-related immune checkpoints.

The suppressor-of-cytokine signaling (SOCS) family of proteins play important roles in NK cell biology by attenuating JAK-STAT–mediated cytokine signaling and NK cell cytotoxicity against cancer.^{8,9} One of its members, the cytokine-inducible Src homology 2–containing protein (CIS), is encoded by the *CISH* gene. CIS contains a central Src homology 2 that interacts with phosphorylated tyrosine motifs in target proteins such as those belonging to the JAK-STAT signaling pathway and a C-terminal 40-amino-acid motif known as the SOCS box that ubiquitinates the target proteins and directs them for proteasomal degradation.^{10,11} CIS is induced by cytokines such as IL-2 and IL-15^{12,13} and is an important intracellular checkpoint in NK cells.¹⁰




Figure 1. CRISPR-Cas9-mediated deletion of *CISH* in iC9/CAR19/IL-15 NK cells. (A) Schematic representation of CRISPR-Cas9-mediated *CISH* KO using 2 guide RNAs (gRNA) targeting exon 4 of the *CISH* gene. PAM, protospacer-adjacent motif. (B-C) CB-NK cells were expanded with K562 based feeder cells and IL-2 and then either left NT or transduced with a retroviral vector expressing iC9/CAR19/IL-15 construct on day 4 (D4) of expansion. On day 7 (D7) of expansion, NT and iC9/CAR19/IL-15-expressing CB-NK cells were nucleofected with Cas9 alone (Cas9 mock), Cas9 preloaded with gRNA targeting *CISH* exon 4 (*CISH* KO), or nonnucleofected (wild-type [WT]). The *CISH* KO efficiency was determined by PCR (B) and western blot analysis (C). (D) Sanger sequencing results showing multiple peaks reflecting nonhomologous end-joining (NHEJ) events in NT or iC9/CAR19/IL-15 (CAR) NK cells that underwent *CISH* KO compared with single peaks in control (Cas9 mock). Arrows indicate the base pair position where the gene editing started. (E) Bar graphs showing the relative mRNA expression levels of *CISH* determined on days 0, 7, 14, and 21 of expansion in NT (blue) and iC9/CAR19/IL-15 (red) NK cells by reverse transcription polymerase chain reaction (RT-PCR) ($n = 3$). Note that on days 0 and 7 only data for NT-NK cells are included since the CAR transduction step is performed on day 4 of expansion. 18 S ribosomal RNA (18S) was used as the internal reference gene. Bars represent mean values with standard deviation, * $P \leq .05$.

Given that our CAR19-specific CB-derived NK cells are designed to secrete IL-15, we hypothesized that CIS would be a logical checkpoint to target to enhance their antitumor potency. Here, we show that a combined strategy of IL-15 CAR engineering and *CISH* knockout (KO) in CB-derived NK cells significantly improved tumor control. This gain of effector function is attributed to enhanced IL-15 signaling secondary to *CISH* KO, with consequent activation of the Akt/mTORC1/c-MYC pathway and increased NK cell glycolysis in response to tumor. Thus, we demonstrate that deleting a critical cytokine checkpoint in IL-15-secreting CAR-NK cells improves their metabolic “fitness,” permitting greater in vivo persistence and cytotoxic function. Our data support the use of a 2-step strategy that combines engineering CAR-NK cells to secrete IL-15 with cytokine checkpoint gene editing to further enhance their therapeutic potential in the clinic.

Materials and methods

Retrovirus transfection and transduction

The retroviral vector encoding iC9.CAR19.CD28-ζ-2A-IL-15 was kindly provided by Gianpietro Dotti (University of North

Carolina).^{14,15} CAR19.CD28-ζ (without IL-15) was used as a control.

CRISPR-Cas9 gene editing of *CISH*

CISH KO was performed using ribonucleoprotein (RNP) complex, in both NT and CAR-NK cells (for details, see supplemental Methods, available on the *Blood* Web site). To assess KO efficiency, we used polymerase chain reaction (PCR) gel electrophoresis, western blot, and Sanger sequencing. Details on the protocols are included in supplemental Methods.

NK cell functional and cytotoxicity assays

Cytokine production, degranulation, chromium release assay, Incucyte real-time assay, and annexin V/DRAQ7 viability assays were used as previously described.⁶ Details of these assays are provided in the supplemental Methods.

Mass cytometry and antibody conjugation

A panel comprising 37 metal-tagged antibodies was used for the in-depth characterization of NK cells¹⁶ (supplemental Table 1 and supplemental Methods).




Figure 2. Phenotype and molecular signature of iC9/CAR19/IL-15 CISH KO NK cells. (A) Comparative heatmap of mass cytometry data showing the expression of NK cell surface markers, transcription factors, and cytotoxicity markers in iC9/CAR19/IL-15 CISH KO compared with iC9/CAR19/IL-15 control NK cells. Each column represents a separate cluster identified by FlowSOM analysis, and each row reflects the expression of a certain marker for each annotation. Color scale shows the expression level for each marker, with

Seahorse assays

The extracellular acidification rate (ECAR) and oxygen consumption rate were measured using the Agilent Seahorse XFe96 Analyzer (Agilent) per the manufacturer's instructions. NT-NK cells (control or *CISH* KO) and CAR-transduced NK cells (control or *CISH* KO) were assayed alone or purified after 2 hours of coculture with Raji. Where indicated, NK cells were preincubated with rapamycin (100 ng/mL, Miltenyi Biotec) for 4 hours prior to the Seahorse assay.

Xenogeneic lymphoma models

We used an aggressive NK-resistant Raji NOD/SCID IL-2R γ null (NSG) xenograft model as previously described.⁶ Mice (10–12 weeks old; The Jackson Laboratory, Bar Harbor, ME) were irradiated with 300 cGy at day –1 and engrafted with FFluc-Raji cells. Where indicated, NT (control or *CISH* KO), CAR19/IL-15 CB-NK (control or *CISH* KO), or CAR19 (no IL-15) CB-NK (control or *CISH* KO) cells were injected through the tail vein. Mice were subjected to weekly bioluminescence imaging (Xenogen IVIS-200 Imaging System).¹⁷ Trafficking, persistence and expansion of NK cells were measured by flow cytometry. The antibodies used for flow cytometry staining are described in detail in the supplemental Methods.

Off-target identification

The genome-wide, unbiased identification of double-stranded breaks enabled by sequencing (GUIDE-seq) method was employed for unbiased discovery of off-target editing events.¹⁸ Details of this technology and target enrichment via rhAmpSeq¹⁹ are included in supplemental Methods.

Additional detailed methods are provided in supplemental Data.

Results

Phenotypic and molecular signaling alterations associated with *CISH* deletion

The central hypothesis of this study predicts that knocking out the *CISH* gene in CAR-NK cells will enhance their effector function against tumor cells, much in the way that targeting PD-1 improves outcomes by removing a critical immune checkpoint in T cells.^{20,21} Our approach for combined retroviral transduction with the iC9/CAR19/IL-15 construct and RNP-mediated gene editing of *CISH* is shown in Figure 1A–B. On day 7, we nucleofected CAR-NK cells with Cas9 alone (Cas9 mock) or Cas9 preloaded with gRNA targeting *CISH* exon 4. The iC9/CAR19/IL-15 transduction efficiency and cell viability on day 7 were >90% and remained stable over time in both control and gene-edited cells (supplemental Figure 1A–B). The efficiency of *CISH* KO was

high (81% to 98%) in both the nontransduced (NT) control and CAR-expressing NK cells by PCR (Figure 1B) and western blot (Figure 1C) and remained stable over time (supplemental Figure 1C–D). This on-target efficiency was confirmed by Sanger sequencing (Figure 1D). Importantly, *CISH* expression in NK cells transduced with either iC9/CAR19/IL-15 or NT (control) and cultured with IL-2 and K562 feeder cells expressing membrane-bound IL-21, 4-1BB ligand, and CD48 (referred to as uAPC) increased over time (Figure 1E). This indicates that CAR-modified and NT-NK cells are subject to the same counter-regulatory circuits leading to modulation of CIS levels.

Next, to gain insight into the phenotypic changes that accompany *CISH* KO in CAR-NK cells, we used cytometry by time of flight and a panel of 37 antibodies against inhibitory and activating receptors, as well as differentiation, homing, and activation markers (supplemental Table 1). *CISH* KO resulted in increased expression of markers of activation and cytotoxicity (Figure 2A), including granzyme B, perforin, TRAIL, and CD3 ζ ; transcription factors such as eomesodermin (eomes) and T-bet; adaptor molecules such as DAP12; and activating co-receptors/proliferation markers such as DNAM, CD25, and Ki67. A similar profile of upregulated markers was identified after *CISH* KO in NT-NK cells (supplemental Figure 2A). Using t-SNE, a t-distributed stochastic neighbor-embedding (t-SNE) algorithm, we observed marked phenotypic differences between control and *CISH* KO iC9/CAR19/IL-15 NK cells, with predominantly proliferative and cytotoxic features (eg, increased expression of CD25, Ki67, CD3 ζ , perforin, and granzyme B) in *CISH* KO iC9/CAR19/IL-15 NK cells (Figure 2B). Despite higher expression of proliferation markers on *CISH* KO iC9/CAR19/IL-15 NK cells on phenotyping, the proliferative capacity of NK cells during in vitro expansion did not differ significantly following *CISH* KO (supplemental Figure 3A). This is likely related to the use of uAPCs that can optimally expand both engineered and nonengineered NK cells in vitro.^{5,17} Moreover, despite the activation phenotype associated with *CISH* KO, we did not observe any evidence of activation-induced cell death in NT *CISH* KO or CAR19/IL-15 *CISH* KO cells following stimulation with tumor targets (supplemental Figure 3B).

To assess the consequences of *CISH* KO on the transcriptomic and signaling pathway responses of NK cells, we performed RNA-sequencing studies of *CISH* KO NT and iC9/CAR19/IL-15 NK cells vs their unmodified controls. *CISH* KO led to upregulation of genes related to inflammatory and immune responses (eg, tumor necrosis factor [TNF] and interferon [IFN] signaling such as TNFRSF12A, MX1, and T-bet regulation such as ZEB2) as well as cytokine signaling (eg, IL1A, IL3RA, and CXCL8) (Figure 2C; supplemental Figure 2B) in both NT and

Figure 2 (continued) red representing higher expression and blue lower expression in iC9/CAR19/IL-15 *CISH* KO NK cells. The t-SNE map generated from FlowSOM analysis in the right panel shows the 20 NK cell metaclusters (MCs) represented in the mass cytometry heatmap in the left panel. (B) Individual t-SNE maps show the expression of selected NK cell markers for iC9/CAR19/IL-15 *CISH* KO compared with iC9/CAR19/IL-15 control NK cells. Color scale indicates signal intensity, ranging from low (blue) to high (red) after arcsine transformation. (C) Global gene expression analysis by RNA sequencing. Heatmap displays the genes that were differentially expressed in purified iC9/CAR19/IL-15 *CISH* KO vs iC9/CAR19/IL-15 control NK cells ($n = 4$). Color scale shows the expression level of each marker, with red representing higher expression and blue lower expression in iC9/CAR19/IL-15 control (CAR) or iC9/CAR19/IL-15 *CISH* KO (CAR KO) NK cells ($q < 0.1$ and absolute log2foldchange > 0.8). (D) GSEA showing enrichment in IFN- γ response, TNF- α signaling via NF- κ B, IL-2/STAT5 signaling, IL-6/JAK/STAT3 signaling and inflammatory response in iC9/CAR19/IL-15 *CISH* KO compared with iC9/CAR19/IL-15 control NK cells. (E) Representative histogram showing enhanced phosphorylation of STAT5 (p-STAT5), STAT3 (p-STAT3) and phospholipase C γ 1 (p-PLC γ 1) in iC9/CAR19/IL-15 *CISH* KO vs iC9/CAR19/IL-15 control NK cells after coculture with Raji cells for 30 minutes. Blue histograms represent CAR control, and red histograms represent CAR *CISH* KO. (F) Bar graphs showing mean fluorescence intensity (MFI) of p-STAT5, p-STAT3, and p-PLC γ 1 in iC9/CAR19/IL-15 *CISH* KO vs iC9/CAR19/IL-15 control NK cells ($n = 3$). Blue bars represent CAR control and red bars represent CAR *CISH* KO. Bars represent mean values with standard deviation. ** $P \leq .01$.

iC9/CAR19/IL-15 NK cells. Gene set enrichment analysis (GSEA) supported enrichment of pathways involved in TNF- α , IFN- γ , IL-2/STAT5, and IL-6/JAK/STAT3 signaling, as well as in those related to inflammatory immune responses (Figure 2D; supplemental Figure 2C). We confirmed our findings at the protein level by showing enhanced phosphorylation of STAT5, STAT3, and phospholipase C γ 1 (PLC γ 1) in *CISH* KO iC9/CAR19/IL-15 NK cells (Figure 2E-F). It is worthwhile to note that CIS and other SOCS proteins have been reported to downregulate CD3 ζ ²² and PLC γ 1²³ in T cells, and our data support a similar effect in NK cells after *CISH* KO for both CD3 ζ (Figure 2A-B) and p-PLC γ 1 (Figure 2E-F). Considered together, these phenotypic and molecular signaling results support the hypothesis that targeting CIS in CAR-NK cells removes an important immune checkpoint.

***CISH* ablation enhances the antitumor activity of iC9/CAR19/IL-15 NK cells**

When tested against CD19⁺ Raji lymphoma cells, our *CISH* KO NT or iC9/CAR19/IL-15 NK cells produced more IFN- γ and TNF- α , and displayed greater degranulation (CD107a) and cytotoxicity against their targets than did their respective NT and iC9/CAR19/IL-15 NK controls (Figure 3A-D). Furthermore, *CISH* KO iC9/CAR19/IL-15 NK cells killed Ramos lymphoma cell line and primary chronic lymphocytic leukemia targets cells ($n = 3$) more efficiently than controls (supplemental Figure 4A-B). This outcome was reinforced by the effect of *CISH* KO on the formation of the immunologic synapse (IS) between NT or iC9/CAR19/IL-15 NK cells and tumor cells. Indeed, polarization of perforin-centroid defined microtubule-organizing center (MTOC) was augmented by *CISH* deletion as reflected by a shortened MTOC-to-IS distance compared with controls (Figure 3E-F), a finding that typically correlates with increased effector cell function and cytotoxicity.²⁴ While we did not observe an upregulation in the expression of adhesion molecules (eg, LFA-1, CD11b, or CD2), *CISH* deletion resulted in an increase in the CAR mean fluorescence intensity (supplemental Figure 5). Upregulation of CAR expression following *CISH* KO is likely related to the increased activation state of the iC9/CAR19/IL-15 NK cells and supports prior reports that cell activation can increase expression of SFG retroviral vector–encoded transgenes.^{14,25}

Robust metabolic changes associated with CIS checkpoint elimination

Although blocking the cytokine checkpoint CIS seemed like a logical approach, we remained concerned over the possible impact of increased IL-15 signaling on prominent metabolic pathways in NK cells. In one negative scenario, long-term exposure to IL-15 could suppress rather than boost metabolic rates, leading to NK cell exhaustion.²⁶ In another scenario, it might produce undue systemic toxicity.^{27,28} We therefore evaluated the effects of *CISH* KO, with or without iC9/CAR19/IL-15 transduction, on 2 major regulators of NK cell metabolism: mTORC1, which controls pathways responsible for proliferation and cytotoxicity,^{29,30} and MYC, which upregulates glucose transporters and glycolytic enzymes that promote glycolysis.³¹ Indeed, GSEA revealed an enrichment of genes involved in phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR, mTORC1, c-MYC, and glycolysis (Figure 4A).

The above results raise a pivotal question: are the metabolic gene expression patterns seen with *CISH* KO distinct, or do they overlap with those seen with unmodified or CAR19/IL-15 NK

cells? The heatmap in Figure 4B displays the various hallmark pathways and how they change (upregulated or downregulated) among the various comparisons. In general, compared with NT-NK cells, each engineering strategy (*CISH* KO or CAR transduction) alone or in combination led to enrichment of metabolic pathways (Figure 4B). We observed some overlap between the pathways upregulated by *CISH* ablation or iC9/CAR19/IL-15 transduction alone; however, the combination of both approaches clearly led to more robust metabolic changes (Figure 4B). Of note, certain pathways were specifically activated after *CISH* KO and were not induced with CAR transduction alone; these included pathways related to cytokine signaling and inflammatory response (Figure 4B).

We next focused on the metabolic pathways that are functionally relevant for NK cell antitumor activity; overall, our linear regression model showed an additive effect of *CISH* ablation and CAR transduction, with the largest increase in PI3K/Akt/mTOR and glycolysis pathways being achieved with a combination of the 2 strategies, suggesting that both genetic manipulations are needed to achieve optimal NK cell effector functions (Figure 4C). This interpretation was confirmed by a greater phosphorylation of Akt and ribosomal protein S6 (S6), a downstream target of mTORC1, and increased expression of c-MYC, an important mediator of glycolysis, in particular in *CISH* KO CAR19/IL-15 NK cells in response to Raji targets (Figure 4D; supplemental Figure 6). Notably, p-S6 and p-Akt were upregulated in *CISH* KO CAR19/IL-15 NK cells even in the absence of Raji, although this was not associated with increased tonic signaling (supplemental Figure 7). It is likely by removing the CIS brake, the endogenously secreted IL-15 by CAR19/IL-15 NK cells can trigger the mTORC1/Akt pathway with a lower threshold of activity. In contrast c-MYC, which is the precursor of glycolysis, was only upregulated in response to Raji tumor. To pursue the functional implications of these findings, we first blocked the mTORC1 pathway by treating the CAR19/IL-15 NK cells ($\pm$ *CISH* KO) with rapamycin and observed a decrease in their cytotoxicity against Raji lymphoma compared with untreated cells (supplemental Figure 8A), which asserts the importance of the mTORC1 pathway as part of the mechanism by which *CISH* KO enhances the cytotoxicity of CAR19/IL-15 NK cells. We then used Seahorse assays to measure the glycolytic response of NK cells to tumor targets and showed that in response to Raji cells, either *CISH* KO alone or CAR transduction alone in NK cells could increase glycolysis, as measured by ECAR, although the best result (and the only statistically significant one) was achieved by combining *CISH* KO and CAR19/IL-15 transduction (Figure 4E-F). Consistent with these findings, CAR-NK cells with *CISH* deletion showed the greatest glucose consumption, when cocultured with Raji, compared with controls (Figure 4G). The addition of rapamycin completely abrogated any glycolytic advantage of *CISH* KO in CAR19/IL-15 NK cells or NT-NK cells (supplemental Figure 8B-C), further supporting the importance of the mTORC1 pathway as an upstream regulator of glycolysis in this setting. Importantly, in the absence of Raji targets, there was no difference in glycolysis among the different NK conditions (supplemental Figure 8D-E) which parallels the c-MYC expression profile. *CISH* KO iC9/CAR19/IL-15 NK cells also had higher oxygen consumption rate compared with control iC9/CAR19/IL-15 NK cells (supplemental Figure 9A) and induced an increase in mitochondria numbers and the mitochondrial/nuclear volume ratio as assessed by confocal microscopy (supplemental Figure 9B-C).




Figure 3. CISH deletion improves function and cytotoxicity of NT and iC9/CAR19/IL-15 NK cells. (A) Representative FACS plots of cytokine production (IFN- γ and TNF- α) and CD107a degranulation by NT control, NT CISH KO, iC9/CAR19/IL-15 control, or iC9/CAR19/IL-15 CISH KO NK cells after coculture with Raji target cells for 6 hours. Inset values indicate the frequency of IFN- γ , TNF- α , and CD107a-positive cells from each group. (B) Bar plots summarize the flow cytometry data on cytokine production (IFN- γ and TNF- α) and CD107a degranulation by NT control (blue bars), NT CISH KO (green bars), iC9/CAR19/IL-15 control (purple bars) or iC9/CAR19/IL-15 CISH KO NK cells (red bars) after coculture with Raji target cells for 6 hours ($n = 3$). Statistical significance is indicated as $*P \leq .05$, $**P \leq .01$, and $****P \leq .0001$; bars represent mean values with standard deviation. (C) Cytotoxicity of NT control, NT CISH KO, iC9/CAR19/IL-15 control, or iC9/CAR19/IL-15 CISH KO NK cells against Raji targets at different effector-to-target (E:T) ratios, as measured by ^{51}Cr -release assay ($n = 3$). The bars represent mean values with standard deviation. The red asterisks represent the statistical significance between iC9/CAR19/IL-15 CISH KO vs iC9/CAR19/IL-15 control NK cells ($*P \leq .05$). The green asterisks represent the statistical significance between NT CISH KO vs NT control NK cells ($***P \leq .001$; $**P \leq .01$). (D) Cytotoxicity of NT control, NT CISH KO, iC9/CAR19/IL-15 control, or iC9/CAR19/IL-15 CISH KO NK cells against Raji targets over 24 hours at 1:1 E:T ratio as measured by Incucyte live-imaging cell killing assay ($n = 3$). Bars represent mean values with standard deviation. At 10 hours, NT CISH KO vs NT control ($P = .04$), iC9/CAR19/IL-15 CISH KO vs iC9/CAR19/IL-15 control ($P = .007$). (E) Confocal microscopy showing representative synapse images of NT control, NT CISH KO, iC9/CAR19/IL-15 control or iC9/CAR19/IL-15 CISH KO NK cells conjugated with Raji cells. Images show conjugates in bright field (BF) or stained with anti-CD19 (green), anti-perforin (red), phalloidin-F-actin (blue), and anti-CAR (gray), and an overlay of fluorescence channels are also shown. (F) NT control, NT CISH KO, iC9/CAR19/IL-15 control, or iC9/CAR19/IL-15 CISH KO NK cells were assessed for their ability to polarize lytic granules to Raji cells as measured by distance from the MTOC to the IS. Results from 3 independent donors are shown. Each data point represents a single IS. Statistical significance is indicated as $*P \leq .05$ and $***P \leq .001$.




Figure 4. Metabolic changes associated with iC9/CAR19/IL-15 CISH KO NK cells. (A) GSEA plots showing enrichment in PI3K/Akt/MTOR, mTORC1, MYC, and glycolysis pathways in iC9/CAR19/IL-15 CISH KO NK cells compared with iC9/CAR19/IL-15 control NK cells. (B) Comparative mean T statistic heat map of RNA sequencing data showing the expression of metabolic pathways in NT control (NT), NT CISH KO (NTKO), iC9/CAR19/IL-15 control (CAR), or iC9/CAR19/IL-15 CISH KO (CARKO) NK cells that are significantly different ($q < 0.01$) in ≥ 1 of the 5 comparisons. Each column represents a separate comparison, and each row reflects the expression of a certain hallmark pathway for

These data suggest that *CISH* KO can also enhance the metabolism of CAR-NK cells by increasing mitochondrial activity.

Finally, we propose a model (visual abstract), in which *CISH* KO in CAR-NK cells enhances IL-15 signaling by releasing a checkpoint brake, in turn leading to increased activation of the Akt/mTORC1 axis and in the presence of tumor ensuing c-MYC activation, culminating in greater glycolytic capacity of CAR-NK cells and a resultant increase in their ability to respond to tumor targets.

CIS checkpoint disruption combined with iC9/CAR19/IL-15 transduction improves tumor control in a Raji lymphoma model

Using an aggressive Raji lymphoma mouse model (Figure 5A), we next investigated whether adoptive transfer of *CISH* KO NK cells in the absence of CAR transduction could boost the control of disease in tumor-bearing mice. First, mice received a single IV infusion of NK cells (10×10^6 /mouse) that were either unmodified (NT control) or electroporated with Cas9 alone (Cas9 control) or had *CISH* KO. The tumor burden, monitored by bioluminescence imaging (BLI), increased in all animals through day 28 of the study, with no significant differences in survival noted between the *CISH* KO group and controls (supplemental Figure 10). We next investigated the in vivo antitumor activity of NK cells modified with both *CISH* KO and iC9/CAR19/IL-15 transduction. Mice received iC9/CAR19/IL-15 or *CISH* KO iC9/CAR19/IL-15 NK cells, and tumor growth was followed by weekly BLI imaging. Survival was monitored and all surviving animals were sacrificed at day 35 and their organs examined for evidence of lymphoma. While animals treated with iC9/CAR19/IL-15 NK cells had evidence of tumor in their organs and succumbed to lymphoma, those treated with *CISH* KO iC9/CAR19/IL-15 were tumor free and did not have evidence of lymphoma in their spleen, liver, or bone marrow (Figure 5B-D; supplemental Figure 11A-B). Since dual-engineered cells had shown greater potency than either modification alone, even at low E:T ratios in vitro, we hypothesized that it would also be more effective at controlling Raji lymphoma cells at lower infusion doses. Indeed, when as few as 3×10^6 *CISH* KO iC9/CAR19/IL-15 NK cells were administered, they significantly improved survival ($P = .003$) and the control of Raji lymphoma compared with control NK cells, although the mice eventually succumbed to tumor by day 46 (Figure 5E-G). The higher dose (10×10^6) of the *CISH* KO iC9/CAR19/IL-15 NK cells eradicated lymphoma in mice, as demonstrated by BLI and pathologic examination, and led to significantly prolonged survival times (Figure 5E-H). This result was associated with improved NK cell persistence (up to 7 weeks after infusion) in mice that received the *CISH* KO iC9/CAR19/IL-

15 cells compared with iC9/CAR19/IL-15 NK controls (Figure 5I; supplemental Figure 11C).

CISH KO was not associated with signs of increased toxicity in mice, including organ damage or increase in systemic inflammatory cytokines or increased weight loss compared with control groups (Figure 5D,H,J; supplemental Figure 12). After the initial weight loss observed in all groups after irradiation, mice treated with *CISH* KO iC9/CAR19/IL-15 cells recovered their weight to baseline over an extended period of follow-up (Figure 5J). Moreover, CAR-NK cells were not detectable in the organs of animals at autopsy, indicating that *CISH* KO does not induce uncontrolled expansion and persistence of CAR-NK cells. We conclude that silencing *CISH* in the context of CAR19/IL-15 transduction in NK cells can secure robust control of tumor cells in vivo without appreciable toxicity.

The presence of IL-15 in the CAR construct is necessary for *CISH* KO-mediated improvement in NK cell function

Since our CAR construct expresses both CAR19 and IL-15, it was important to understand whether the improvement in NK cell function following *CISH* KO is dependent on the presence of IL-15 in the CAR construct. To address this question, we transduced NK cells with a vector expressing CAR19 without the IL-15 transgene (referred to as CAR19 NK cells) and analyzed their *CISH* expression after culture with IL-2 and uAPC. CAR19 NK cells showed a time-dependent increase in *CISH* expression to the same extent as observed with NT control, but to a lower magnitude than in iC9/CAR19/IL-15 NK cells (supplemental Figure 13A). The efficiency of *CISH* KO in CAR19 NK cells was similar to what was achieved in CAR19/IL-15 NK cells (supplemental Figure 13B) and improved their cytotoxicity against Raji in vitro (supplemental Figure 13C) similar to NT-NK cells following *CISH* KO. However, when tested in our Raji lymphoma mouse model, *CISH* KO failed to improve the antitumor activity of CAR19 NK cells in vivo (supplemental Figure 13D-F), pointing to the essential role of IL-15 in mediating the effect of *CISH* KO on CAR-NK cell antitumor activity.

Safety evaluation of *CISH* KO iC9/CAR19/IL-15 NK cells for relapsed/refractory B-cell malignancy

To investigate the possibility that enhanced IL-15 signaling may result in autonomous dysregulated growth of *CISH* KO CB-NK cells, we cultured NT (control or *CISH* KO) or iC9/CAR19/IL-15 CB-NK cells (control or *CISH* KO) in media in the absence of exogenous IL-2 or feeder cells for 45 days. Cultured *CISH* KO NT or iC9/CAR19/IL-15 CB-NK cells did not show signs of abnormal growth over 6 weeks (supplemental Figure 14A), after which the cells stopped expanding. Moreover, we did not observe an

Figure 4 (continued) each annotation. Color scale indicates signal intensity, ranging from lower (blue) to higher (red) expression. (C) Violin plots showing PI3K/Akt/mTORC1 and glycolysis signaling in NT (blue), NT-KO (green), CAR (purple), or CAR-KO (red) NK cells after correction for donor effect. Pathway activity of samples is regressed against donor and the residual is the corrected pathway activity. P values reported are computed relative to NT using the linear regression approach discussed in Materials and methods. $**P \leq .01$. (D) NT control (NT), NT *CISH* KO (NT-KO), iC9/CAR19/IL-15 control (CAR), or iC9/CAR19/IL-15 *CISH* KO (CAR-KO) NK cells were cultured without (–) or with (+) Raji cells for 30 minutes, 1 hour, or 2 hours; NK cells were then purified, and the protein expression levels of p-Akt, Akt, p-S6, S6, c-MYC, and α -tubulin in NK cells were determined by western blot analysis. Representative blots from 2 independent experiments are shown. (E) A series of ECARs was calculated for NT control (blue lines), NT *CISH* KO (green lines), iC9/CAR19/IL-15 control (purple lines), or iC9/CAR19/IL-15 *CISH* KO (red lines) NK cells cocultured with Raji targets for 2 hours and subsequently purified and treated with 2 g/L D-glucose, 1 μ M oligomycin, and 100 mM 2-deoxyglucose (2-DG). A representative graph from 5 independent experiments is shown. (F) Box plots summarize the ECAR data by NT control (blue box), NT *CISH* KO (green box), iC9/CAR19/IL-15 control (purple box), or iC9/CAR19/IL-15 *CISH* KO (red box) NK cells cocultured with Raji ($n = 5$). Statistical significance is indicated as $*P \leq .05$; bars represent mean values with standard deviation. (G) Bar graph summarizes the glucose concentration in the supernatant of the different NK cell conditions cocultured with Raji for 2 hours: NT control (blue), NT *CISH* KO (green), iC9/CAR19/IL-15 control (purple), or iC9/CAR19/IL-15 *CISH* KO (red) NK cells ($n = 3$). Bars represent mean values with standard deviation ($**P \leq .01$).




Figure 5. CISH KO iC9/CAR19/IL-15 NK cells improve tumor control and survival in a Raji lymphoma mouse model at low infusion doses. (A) Schematic diagram representing the timeline of the in vivo experiments. (B) BLI imaging of an independent mouse experiment where mice received either Raji alone or Raji plus 10×10^6 CAR19/IL-15 control or Raji plus 10×10^6 CAR19/IL-15 CISH KO ($n = 5$ mice per group). *This mouse died accidentally during bleeding. (C) Survival curve for the 3 groups of mice described in panel B (Raji alone, green; Raji plus 10×10^6 CAR19/IL-15 control, blue; Raji plus 10×10^6 CAR19/IL-15 CISH KO, red). Statistical significance is represented by * $P \leq .05$ for the comparison of the red and blue curves and ** $P \leq .01$ for the comparison of the blue and gray curves. (D) Graph representing the body weights of mice over time in the 3 different

increase in the expression of genes related to chromosomal instability³² such as aurora kinases or genes associated with DNA damage following *CISH* KO (supplemental Figure 14B).

Even though *CISH* KO CAR-NK cells lacked evidence of serious toxicity in our in vivo model, we planned additional in vitro and in vivo experiments to ascertain that *CISH* KO CAR-NK cells could be swiftly eliminated in the event of toxicity in early phase clinical testing. Thus, we relied on the presence of *iC9* as a suicide gene in our vector to confirm that *CISH* KO CAR-NK cells could be induced to undergo apoptosis in the presence of a small-molecule dimerizer, AP1903. The addition of as little as 10 nM of AP1903 to cultures of CAR-NK cells induced their apoptosis within 4 hours, and *CISH* KO did not affect the action of the dimerizer (supplemental Figure 15A). The suicide gene was also effective at eliminating the CAR-NK cells in vivo (supplemental Figure 15B-C). Mice engrafted with Raji tumor received either control or *CISH* KO CAR-NK cells ($n = 5$ mice per group) followed by treatment with the dimerizer on days 7 and 9 after NK cell infusion. The animals were then sacrificed on day 12. Administration of the small-molecule dimerizer resulted in a striking reduction of the transduced cells (both control and *CISH* KO) in the blood and tissues (liver, spleen, and bone marrow) in all treated mice (supplemental Figure 15B-C).

Identifying possible off-target editing events mediated by the CRISPR-Cas9 RNP complexes is crucial before the approach described here can be moved to the clinic. Thus, we used Guide-seq and rhAmpSeq technologies (Integrated DNA Technologies [IDT]) to assess genome-wide off-target effects for our *CISH* gRNAs. Guide-seq experiments were performed using HEK293 cells that constitutively express *Streptococcus pyogenes* Cas9 nuclease paired with highly modified synthetic gRNAs¹⁸ to identify off-target sites with the highest potential to be edited for each CRISPR RNA (crRNA) (Figure 6A-B). Potential Cas9 off-target cleavage sites were then quantified in NK cells electroporated with RNP complexes targeting the *CISH* locus using rhAmpSeq technology. Cells treated with wild-type *S pyogenes*. Cas9 protein had a low frequency of off-target editing events with either crRNA1, crRNA2, or the combination of both crRNAs (Figure 6C-D). The use of a high-fidelity Cas9 protein (Alt-R HiFi Cas9 v3; IDT)³³ further reduced the off-target events to $< 0.5\%$ (Figure 6C-D). These data support the translation of this approach to the clinic.

Discussion

NK cell differentiation, effector function and survival, defined as 'fitness', are coupled to metabolic reprogramming processes. However, signals and checkpoints that regulate NK cell fitness

and function in the tumor microenvironment are not well defined. Our study focuses on the impact of targeting CIS, a negative regulator of cytokine signaling^{10,34} in CAR-NK cells engineered to constitutively express IL-15.

Having demonstrated the antitumor activity of armored CAR-NK cells preclinically and in the clinic,^{5,6} we exploited the potential mechanistic synergy that could be achieved by deleting a cytokine checkpoint in IL-15-secreting CAR-NK cells. Here we report that combining IL-15-secreting CAR-NK cells with *CISH* deletion enhances antitumor activity more than either strategy alone. Using a xenograft mouse model of NK-resistant Raji lymphoma, we showed that *CISH* KO CAR19/IL-15 CB-NK cells persist twice as long as control CAR19/IL-15 NK cells. We attribute this gain of function to IL-15-driven Akt/mTORC1 and MYC signaling secondary to removal of the CIS checkpoint, with a consequent increase in glycolytic activity. These data are consistent with a recent report showing that deleting *CISH* in iPSC NK cells improves their metabolism and antitumor activity.³⁴ Our findings have clinical relevance because they establish, to our knowledge for the first time, proof-of-principle that targeting a critical cytokine checkpoint in cytokine-secreting armored CAR-NK cells promotes their fitness and endows them with superior antitumor function.

This increased antitumor activity was not associated with higher toxicity in the animals. While the NSG mouse model has limitations for the study of cytokine release syndrome,³⁵ the absence of overt toxicity such as rapid weight loss and early deaths support the safety of our approach. A legitimate concern with *CISH* KO is that in the absence of a cytokine checkpoint, IL-15 may drive malignant transformation of CAR-NK cells. However, our extensive studies using transcriptomic analysis, autonomous growth experiments, and in vivo studies did not show any evidence of long-term toxicity or malignant transformation of *CISH* KO CAR19/IL-15 NK cells.

Previous reports have shown that *CISH* deletion in NK cells is beneficial only in murine tumor models where IL-15 or IL2 was present in the tumor microenvironment or administered exogenously.^{10,36} In our study in xenografted mice, there was no appreciable increase in the activity of NT NK cells or CAR19 NK cells (without IL-15 transgene) after *CISH* KO; the only improvement was noted in mice treated with *CISH* KO CAR19/IL-15 NK cells. This suggests that the robust antitumor activity of *CISH* KO CAR-NK cell depends upon the availability of IL-15 in the tumor microenvironment. Thus, incorporation of the *IL-15* gene in the CAR construct, which avoids the toxicities seen with systemic IL-15,^{27,28} likely played an important role in the enhanced antitumor activity of *CISH* KO iC9/CAR19/IL-15 NK cells in our tumor model. Given the absence or limited concentration

Figure 5 (continued) groups described in panel B. Bars represent mean values with standard deviation. (E) BLI data from 5 groups of NSG mice treated with Raji alone ($n = 5$), Raji plus 1 dose of 3×10^6 of iC9/CAR19/IL-15 control NK cells ($n = 5$) or iC9/CAR19/IL-15 *CISH* KO NK cells ($n = 5$), or Raji plus 1 dose of 10×10^6 of iC9/CAR19/IL-15 control NK cells ($n = 5$) or iC9/CAR19/IL-15 *CISH* KO NK cells ($n = 3$). (F-G) The average radiance (F) and survival curves (G) are shown for the 5 groups of mice described in panel E. Statistical significance is represented by $*P \leq .05$ or $**P \leq .01$. (H) Photomicrographs of hematoxylin and eosin (H&E) and immunohistochemical CD20 staining of liver (top) and bone marrow (BM) (bottom) from mice engrafted with Raji B cell lymphoma either untreated or treated with iC9/CAR19/IL-15 *CISH* KO or iC9/CAR19/IL-15 CTLR NK cells (10×10^6 dose level). Representative images show absence of neoplastic B cells in liver and bone marrow of a mouse treated with iC9/CAR19/IL-15 *CISH* KO NK cells in comparison with similar treatment with iC9/CAR19/IL-15 NK cells retaining *CISH* expression. Images were taken at $10\times$ (liver) and $5\times$ (bone marrow) using a Leica DFC 495 camera. (I) Bar graph showing the percentage of NK cells (CD3⁺CD56⁺CD45⁺) present in peripheral blood from mice treated with iC9/CAR19/IL-15 control vs iC9/CAR19/IL-15 *CISH* KO NK cells at days 7, 14, 21, and 28. Bars represent mean values with standard deviation. Statistical significance is represented by $*P \leq .05$ or $**P \leq .01$. (J) Graph showing body weights of NSG mice groups described in panel E over time.




Figure 6. Identification of Cas9 off-target sites by GUIDE-seq and quantification of potential Cas9 off-target cleavage sites using rhAmpSeq technology. (A) Sequences of off-target sites identified by GUIDE-seq for 2 guides targeting the *CISH* locus. The guide sequence is listed on top with off-target sites shown below. The on-target site is identified with a black square. Mismatches to the guide are shown and highlighted in color with insertions shown in gray. The number of GUIDE-seq sequencing reads are shown to the right of each site. 10 μ M Alt-R crRNA XT complexed to Alt-R transactivating CRISPR RNA was delivered into HEK293 cells that constitutively express Cas9 nuclease by nucleofection. (B) Pie charts indicate the fractional percentage of the total unique, CRISPR-Cas9-specific read counts that are on-target (red) and off-target (blue). Total editing at the on- and off-target sites identified by GUIDE-seq was measured using rhAmpSeq, a multiplexed targeted enrichment approach for next-generation sequencing. For each of the 2 *CISH* targeting guides, amplicons were designed around each Cas9 cleavage site with reads $>1\%$ of the on-target GUIDE-seq reads. RNP complexes formed with either WT Cas9 (blue) or Alt-R HiFi Cas9 (red) were delivered via electroporation into expanded NK cells. (C) Insertion/deletion formation at each targeted locus for *CISH* guide 1 (panel 1, 11-plex) and *CISH* guide 2 (panel 2, 70-plex) when a single RNP complex was delivered. The on-target locus is indicated with a black asterisk underneath the first 2 bars of each graph. (D) Insertion/deletion formation at each targeted locus when *CISH* guide 1 and *CISH* guide 2 were codelivered. The on-target locus is indicated with a black asterisk underneath the first 2 bars of each graph.

of IL-15 in the microenvironment of some cancers, expressing this cytokine in the CAR construct is essential to achieving an optimal therapeutic effect from *CISH* KO.

Our results suggest that removal of the CIS checkpoint may increase the metabolic fitness of armored CAR-NK cells by enhancing the activity of downstream metabolic pathways. In the model we propose (visual abstract), *CISH* KO releases the brake on IL-15 signaling, which in turn enhances Akt/mTORC1 activity,³⁰ leading to upregulation of c-MYC and therefore glycolysis, specifically in response to tumor targets. We have previously shown that upon activation, CAR19/IL-15 NK cells secrete more IL-15.⁶ We now propose that upon activation by the tumor, the higher levels of IL-15 in the microenvironment leads to increased IL-15/Akt/mTORC1 and c-MYC signaling in *CISH* KO CAR19/IL-15 NK cells. We would emphasize that in our studies, c-MYC expression and the resultant shift in metabolism toward aerobic glycolysis³¹ in *CISH* KO iC9/CAR19/IL-15 CB-derived NK cells were only apparent when the NK cells were cultured with tumor targets. This observation is important, as an exaggerated increase in glycolysis in ex vivo-expanded T cells has been reported to severely impair the ability of CD8⁺ T cells to persist long-term and form memory cells in vivo.³⁷ Hence, careful tuning of NK cell metabolism to ensure a timely increase in aerobic glycolysis in response to tumor stimulation would be desirable.

In summary, this is the first report of a genetic engineering strategy combining armored CAR engineering and *CISH* deletion in CB-derived NK cells. When tested in a preclinical tumor model, this cellular product eliminated CD19⁺ lymphoma cells without signs of serious toxicity. Our findings support the merging of armored CAR engineering and cytokine checkpoint gene editing to enhance the therapeutic potential of NK cells in the clinic.

Acknowledgments

Supported in part by the generous philanthropic support to The University of Texas MD Anderson Cancer Center Moonshot program, by grants from the Cancer Prevention and Research Institute of Texas (RP160693) and the National Institutes of Health, National Cancer Institute (1 R01 CA211044-01 and PO1 5P01CA148600-03) and by Cancer Center Support (CORE) grant CA016672 (to the Flow Cytometry and Cellular Imaging Facility and the A sequencing core facility at Anderson Cancer Center). The authors acknowledge the support of a Deutsche Knochen Mark Spenderdatei Mechthild Harf research grant and a Society for Immunotherapy of Cancer-Amgen Cancer Immunotherapy in Hematologic Malignancies fellowship award (M.D.).

Authorship

Contribution: M.D., R.B., and P.P.B. performed experiments and interpreted and analyzed data; N.B. performed western blot and Seahorse assay experiments and interpreted and analyzed data; E.G.,

N.U., A.K.N.C., J.L., G.O., E.E., M. Kaplan, V.N., M.B., L.B., X.W., and X.R.J. assisted with experiments; V.M., Y.X., Y.S., K.C., and J.W. assisted with RNA-sequencing analysis; D. Mak assisted with mass cytometry sample processing; S.K. and N.P. assisted with mass cytometry analysis; M.F., A.R., and N.V. performed and commented on confocal microscopy for mitochondrial studies; M.S.S., G.R.R., R.T., M.S.M., G.K., H.L., and M.A.B. performed off-target effect experiments and analysis and commented on the manuscript; N.W.F. performed pathologic examination and staining of mice tissues; M. Konopleva, N.V., E.J.S., R.E.C., K.C., E.L., S. Ang, S. Acharya, R.J.S., S.L., and L.S. commented on the manuscript; D. Marin, M.M., L.N.K., N.I., M.S., L.L., H.S., F.L.W.I.L., P.P.B., and Y.L. provided advice on experiments and commented on the manuscript; K.R. and M.D. designed and directed the study; and K.R., M.D., and L.M.-F. wrote the manuscript.

Conflict-of-interest disclosure: K.R., M.D., R.B., P.P.B., E.L., E.J.S., R.E.C., D.M., and The University of Texas MD Anderson Cancer Center (MDACC) have an institutional financial conflict of interest with Takeda Pharmaceutical for the licensing of the technology related to the research reported here. MDACC has implemented an Institutional Conflict of Interest Management and Monitoring Plan to manage and monitor the conflict of interest with respect to MDACC's conduct of any other ongoing or future research related to this relationship. M.A.B., M.S.S., G.R.R., M.S.M., G.K., and R.T. are employed by IDT, which manufactures reagents similar to some described in the paper; M.A.B., M.S.M., R.T., and G.R.R. own equity in DHR, the parent company of IDT. H.L. is a consultant for IDT. The remaining authors declare no competing financial interests.

ORCID profiles: M.D., 0000-0002-6026-8397; N.B., 0000-0003-0618-4798; M.F., 0000-0001-9971-4166; A.R., 0000-0002-1197-0198; G.O., 0000-0002-8548-5072; M. Kaplan, 0000-0003-0079-8617; S. Acharya, 0000-0002-3907-9321; X.R.J., 0000-0002-8938-8886; S.K., 0000-0002-0347-4207; N.P., 0000-0003-1873-5542; L.B., 0000-0003-2624-8576;

R.T., 0000-0003-1283-9594; M.S.S., 0000-0002-9189-2547; G.R.R., 0000-0003-4634-5787; M.S.M., 0000-0002-8737-785X; M.A.B., 0000-0002-4218-857X; H.L., 0000-0003-4874-2874; N.W.F., 0000-0002-7711-6031; K.C., 0000-0003-4013-5279; M. Konopleva, 0000-0002-9347-2212; R.E.C., 0000-0002-4314-5037.

Correspondence: Katayoun Rezvani, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4009; e-mail: krezvani@mdanderson.org.

Footnotes

Submitted 22 June 2020; accepted 29 August 2020; prepublished online on *Blood* First Edition 9 September 2020. DOI 10.1182/blood.2020007748.

*M.D. and R.B. contributed equally to this study.

All requests for raw data and materials will be reviewed by MD Anderson Cancer Center to verify if the request is subject to any intellectual property or confidentiality obligations. Any data and materials that can be shared by the corresponding author will be released freely or via a Material Transfer Agreement if deemed necessary.

The online version of this article contains a data supplement.

There is a *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

REFERENCES

- Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. *Nat Rev Cancer*. 2016;16(1):7-19.
- Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. *Curr Opin Immunol*. 2018;51:146-153.
- Mehta RS, Shpall EJ, Rezvani K. Cord blood as a source of natural killer cells. *Front Med (Lausanne)*. 2016;2:93.
- Sarvaria A, Jawdat D, Madrigal JA, Saudemont A. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. *Front Immunol*. 2017;8:329.
- Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. *N Engl J Med*. 2020;382(6):545-553.
- Liu E, Tong Y, Dotti G, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. *Leukemia*. 2018;32(2):520-531.
- Pfefferle A, Huntington ND. You have got a fast CAR: chimeric antigen receptor NK cells in cancer therapy. *Cancers (Basel)*. 2020;12(3):E706.
- Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. *Stem Cells*. 2001;19(5):378-387.
- Linossi EM, Babon JJ, Hilton DJ, Nicholson SE. Suppression of cytokine signaling: the SOCS perspective. *Cytokine Growth Factor Rev*. 2013;24(3):241-248.
- Delconte RB, Kolesnik TB, Dagley LF, et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. *Nat Immunol*. 2016;17(7):816-824.
- Zhang JG, Farley A, Nicholson SE, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. *Proc Natl Acad Sci USA*. 1999;96(5):2071-2076.
- Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. *Arthritis Res Ther*. 2005;7(3):100-110.
- Inagaki-Ohara K, Hanada T, Yoshimura A. Negative regulation of cytokine signaling and inflammatory diseases. *Curr Opin Pharmacol*. 2003;3(4):435-442.
- Hoyos V, Savoldo B, Quintarelli C, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. *Leukemia*. 2010;24(6):1160-1170.
- Vera J, Savoldo B, Vigouroux S, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. *Blood*. 2006;108(12):3890-3897.
- Li L, Chen H, Marin D, et al. A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. *Blood Adv*. 2019;3(23):4117-4130.
- Shah N, Martin-Antonio B, Yang H, et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. *PLoS One*. 2013;8(10):e76781.
- Tsai SQ, Zheng Z, Nguyen NT, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. *Nat Biotechnol*. 2015;33(2):187-197.
- Dobosy JR, Rose SD, Beltz KR, et al. RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers. *BMC Biotechnol*. 2011;11(1):80.
- Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. *J Clin Invest*. 2016;126(8):3130-3144.
- Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. *Blood*. 2017;129(8):1039-1041.
- Matsuda T, Yamamoto T, Kishi H, Yoshimura A, Muraguchi A. SOCS-1 can suppress CD3zeta- and Syk-mediated NF-AT activation in a non-lymphoid cell line. *FEBS Lett*. 2000;472(2-3):235-240.
- Palmer DC, Guittard GC, Franco Z, et al. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. *J Exp Med*. 2015;212(12):2095-2113.

24. Mukherjee M, Mace EM, Carisey AF, Ahmed N, Orange JS. Quantitative imaging approaches to study the CAR immunological synapse. *Mol Ther*. 2017;25(8):1757-1768.
25. Krenciute G, Prinzing BL, Yi Z, et al. Transgenic expression of IL15 improves antitumor activity of IL13Rα2-CAR T cells but results in antigen loss variants. *Cancer Immunol Res*. 2017;5(7):571-581.
26. Felices M, Lenvik AJ, McElmurry R, et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. *JCI Insight*. 2018;3(3):96219.
27. Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. *J Clin Oncol*. 2015;33(1):74-82.
28. Waldmann TA, Lugli E, Roederer M, et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. *Blood*. 2011;117(18):4787-4795.
29. Donnelly RP, Loftus RM, Keating SE, et al. mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function. *J Immunol*. 2014;193(9):4477-4484.
30. Marçais A, Cherfils-Vicini J, Viant C, et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. *Nat Immunol*. 2014;15(8):749-757.
31. Donnelly RP, Finlay DK. Glucose, glycolysis and lymphocyte responses. *Mol Immunol*. 2015;68(2 Pt C):513-519.
32. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. *Nat Genet*. 2006;38(9):1043-1048.
33. Vakulskas CA, Dever DP, Rettig GR, et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. *Nat Med*. 2018;24(8):1216-1224.
34. Zhu H, Blum RH, Bernareggi D, et al. Metabolic reprogramming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. *Cell Stem Cell*. 2020;27(2):224-237.e6.
35. Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. *Nat Med*. 2018;24(6):731-738.
36. Putz EM, Guillerey C, Kos K, et al. Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. *Oncotarget*. 2017;6(2):e1267892.
37. Sukumar M, Liu J, Ji Y, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. *J Clin Invest*. 2013;123(10):4479-4488.



SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT: 800.176.089-2

COMPROBANTE DE RECAUDO SISTEMA SIPI

Radicado: NC2020/0015168
Recibo: 24-43130
Fecha: 31/05/2024

CAROLINA MERCEDES DAZA MONTALVO
CC: 66.783.790
Pago PSE No: 973421
CUS: 674744308

Patente PCT
CÉLULAS ASESINAS NATURALES DISEÑADAS PARA EXPRESAR RECEPTORES DE ANTÍGENO
QUIMÉRICO CON BLOQUEO DE PUNTOS DE CONTROL INMUNITARIO

Detalle del pago

Id.	Rentístico	Concepto y Servicio	Cant.	Val. Unit.	Subtotal
1	50005-01-03	Modificaciones / Correcciones al registro Patente PCT (DESCUENTO INTERNET)	1	\$ 214,000	\$ 214,000
2	50005-01-01	Solicitud examen de patentabilidad Patente PCT (DESCUENTO INTERNET)	1	\$ 1,447,500	\$ 1,447,500
TOTAL					\$ 1,661,500